Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin

Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin

Bibliographic Details
Main Authors:	Nicholas Power, Fiona Lynch, David W. Denning, Rohit Bazaz
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	Journal of Global Antimicrobial Resistance
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213716520302605

Similar Items

Posaconazole
by: Bhattacharya M, et al.
Published: (2010-01-01)

Posaconazole for lobomycosis
by: Alessandro C. Pasqualotto, et al.
Published: (2021-03-01)

Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis
by: Alyssa Mezochow, et al.
Published: (2019-07-01)

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
by: Whitley M. Yi, et al.
Published: (2017-09-01)

Posaconazole‐induced Pseudohyperaldosteronism
by: Jutamart Tantiprawan, et al.
Published: (2021-03-01)

Determination of Posaconazole in Plasma/Serum by High-Performance Liquid Chromatography with Fluorescence Detection
by: Peter H. Tang
Published: (2017-05-01)

Posaconazole as rescue therapy in African histoplasmosis
by: Daniel Gonçalves, et al.
Published: (2013-01-01)

Posaconazole as rescue therapy in African histoplasmosis
by: Daniel Gonçalves, et al.

Posaconazole as rescue therapy in African histoplasmosis
by: Daniel Gonçalves, et al.
Published: (2013-02-01)

Role of posaconazole in the treatment of oropharyngeal candidiasis
by: Voichita Ianas, et al.
Published: (2010-06-01)

Posaconazole: An Update of Its Clinical Use
by: Simon Leung, et al.
Published: (2015-10-01)

Comparison of clinical pharmacology of voriconazole and posaconazole
by: Beata M. Sienkiewicz, et al.
Published: (2016-12-01)

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole
by: Charlotte Boughton, et al.
Published: (2018-02-01)

Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
by: Syed Hani Abidi, et al.
Published: (2021-05-01)

Attainment of therapeutic vancomycin level within the first 24 h
by: Patrick M. Honore, et al.
Published: (2019-06-01)

Gynecomastia and hypertension in a patient treated with posaconazole
by: George R. Thompson III, et al.
Published: (2020-12-01)

Posaconazole in the management of refractory invasive fungal infections
by: Stefan Langner, et al.
Published: (2008-09-01)

Posaconazole‐induced hypertension in children with cystic fibrosis
by: Rachael Marpole, et al.
Published: (2021-09-01)

The correlation between raised liver enzyme levels and high concentrations of rifampicin and its metabolites : 25-desacetyl rifampicin and 3-formyl rifampicin
by: Reuter, Galya Dominique
Published: (2014)

Posaconazole Induced Diffuse Lentigines: A Case Report
by: Kittipoom Chinhiran, et al.
Published: (2018-06-01)

The Impact of Gelatin on the Pharmaceutical Characteristics of Fucoidan Microspheres with Posaconazole
by: Marta Szekalska, et al.
Published: (2021-07-01)

UV Spectrophotometric method for determination of posaconazole: comparison to HPLC
by: Andressa S. Bitencourt, et al.
Published: (2015-10-01)

Posaconazole Induced Diffuse Lentigines: A Case Report
by: Kittipoom Chinhiran, M.D., et al.
Published: (2018-03-01)

Primary Adrenal Insufficiency Secondary to Chronic Posaconazole Use
by: Daniela Pirela Araque, MD, et al.
Published: (2020-03-01)

Selenium as a therapeutic adjuvant for isoniazid/rifampicin-induced hepatotoxicity
by: Elias Adikwu, et al.
Published: (2020-01-01)

Posaconazole treatment of refractory eumycetoma and chromoblastomycosis Tratamento com posaconazol de casos de cromoblastomicose e micetoma maduromicótico resistentes a outros antifúngicos
by: Ricardo Negroni, et al.
Published: (2005-12-01)

Attainment of therapeutic vancomycin level within the first 24 h: Authors' response
by: João Pedro Baptista, et al.
Published: (2019-11-01)

Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations
by: Ivulich, S, et al.
Published: (2018)

Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole in Adult Patients with Acute Myeloid Leukemia: A Single-Center Experience
by: Hummert, Shelly, et al.
Published: (2014)

Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: Factors affecting trough plasma concentrations
by: Ivulich, S., et al.
Published: (2018)

New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review
by: Veselov A.V.
Published: (2016-11-01)

Improvement of patient compliance with the use of Posaconazole in a BMT unit
by: C.C. Beukes
Published: (2014-04-01)

Breakthrough invasive fungal infection under the use of posaconazole and voriconazole
by: Sze-Hwei Lee, et al.
Published: (2016-05-01)

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
by: Sarah Allegra, et al.
Published: (2017-11-01)

Posaconazole: A Review of Drug Interactions with HIV Antiretroviral Agents
by: Mara Poulakos, et al.
Published: (2014-03-01)

Evaluation of the role of itraconazole and posaconazole in viral infection as immunomodulatory drugs
by: Falah Hasan Obayes AL-Khikani
Published: (2021-01-01)

Combination With Tomatidine Improves the Potency of Posaconazole Against Trypanosoma cruzi
by: Marianne Rocha-Hasler, et al.
Published: (2021-03-01)

Background Characteristics of the Individuals Attaining Higher Education in India: A Sociological Study of Srinagar City
by: Rabiya Yaseen Bazaz, et al.
Published: (2020-09-01)

THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: G. A. Klyasova, et al.
Published: (2017-11-01)

The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies
by: Veselov A.V.
Published: (2020-05-01)

Cannot write session to /tmp/vufind_sessions/sess_3uf7i21ptebhl5d9fsg1ar21fj